Caliway has completed the End-of-Phase 2 (EOP2) meeting with the U.S. FDA for CBL-514, the world's first investigational drug for large-area subcutaneous fat reduction developed under the 505(b)(1) regulatory pathway. The company has received the EOP2 meeting minutes, confirming the...
Hence then, the article about caliway announces successful eop2 meeting with the fda for cbl 514 in reduction of abdominal subcutaneous fat was published today ( ) and is available on PR Newswire ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.
Read More Details
Finally We wish PressBee provided you with enough information of ( Caliway Announces Successful EOP2 Meeting with the FDA for CBL-514 in Reduction of Abdominal Subcutaneous Fat )
Also on site :
- Natural gas line rupture stops traffic on 5 Freeway in Castaic
- 30–35 terrorists on radar: Army steps up counterterror ops in J&K; intense vigil amid 'Chillai Kalan'
- No. 20 Virginia notches first 11-win season by beating 25th-ranked Missouri in the Gator Bowl